___

• 1. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251– 3255.
• 2. Laursen BS, Sørensen HP, Mortensen  KK, Sperling-Petersen HU. Initiation of protein synthesis in bacteria. Microbiol Mol Biol Rev 2005; 69: 101–123.
• 3. Livermore DM. Linezolid in vitro mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51: ii9–ii16.
• 4. Kloss PL, Xiong DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294: 93–101.
• 5. Wong A, Reddy SP, Smyth DS, Aguero-Rosenfeld ME, Sakoulas G, Robinson DA. Polyphyletic emergence of linezolid-resistant Staphylococci in the United States. Antimicrob Agents Chemother 2010; 54: 742–748.
• 6. Long KS,  Poehlsgaard J,  Kehrenberg C,  Schwarz S,  Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50: 2500–2505.
• 7. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing, Approved standard M100-S20. 20th edition. Wayne, PA, USA; 2010.
• 8. Hong T, Xiangyang L, Wang J, Sloan C, Cicogna C. Sequential linezolid-resistant Staphylococcus epidermidis isolates with G2576T mutation. J Clin Microbiol 2007; 45: 3277–3280.
• 9. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab 2009; 10: 2–12.
• 10. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 53–66.
• 11. Stefani S, Bongiorno D, Mongelli G, Campanile F. Linezolid resistance in Staphylococci. Pharmaceuticals 2010; 1988–2006.
• 12. Afşar I, Barış I, Şener AG, Köksal V, Demirci M. Linezolidresistant Enterococcus faecium: the first G2576T mutation in Turkey. Mikrobiyol Bul 2012; 46: 516–518.
• 13. Baos E, Candel FJ, Merino P, Pena I, Picazzo JJ. Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolidresistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 76: 325–329.
• 14. Ağalar C, Göçmen JS, Kılıç D, Kaygusuz S, Karabıçak Ç. Üçüncü basamak bir referans hastanesinde izole edilen metisilin dirençli stafilokok suşlarında duyarlılık. J Clin Exp Invest 2012; 3: 71–74 (in Turkish).
• 15. Öksüz L, Gürler N. Susceptibility of clinical methicillinresistant Staphylococci isolates to new antibiotics. J Infect Dev Ctries 2013; 7: 825–831.
• 16. Polacek N, Mankin AS. The ribosomal peptidyl transferase center: structure, function, evolution, inhibition. Crit Rev Biochem Mol Biol 2005; 40: 285–311.
• 17. Aoki HL, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, Thomas RC,  Shinabarger DL, Ganoza MC. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother 2002; 46: 1080–1085.
• 18. Mitchell P, Stade K, Osswald M, Brimacombe R. Site-directed cross-linking studies on the E. coli tRNA-ribosome complex: determination of sites labelled with an aromatic azide attached to the variable loop or aminoacyl group of tRNA. Nucleic Acids Res 1993; 21: 887–896.
• 19. Rinke-Appel J, Jünke N, Osswald M, Brimacombe R. The ribosomal environment of tRNA: crosslinks to rRNA from positions 8 and 20:1 in the central fold of tRNA located at the A, P, or E site. RNA 1995; 1: 1018–1028.